The U.K.’s National Institute for Health and Care Excellence (NICE) will reevaluate Eli Lilly’s Alzheimer’s drug, donanemab, for National Health Service (NHS) use. This reassessment follows a successful appeal by the company.
NICE previously determined in 2024 that the drug was not a cost-effective use of taxpayer money. The new review will reconsider the drug's impact on caregiver quality of life. The evaluation also includes treatment administration costs.
Eli Lilly executives welcomed the decision for patients in England.